Chapter 1: Introduction
 1.1 Research Objectives
 1.2 Research Methodology
 1.3 Research Process
 1.4 Scope and Coverage
  1.4.1 Market Definition
  1.4.2 Key Questions Answered
 1.5 Market Segmentation

Chapter 2:Executive Summary

Chapter 3:Growth Opportunities By Segment
 3.1 By Type
 3.2 By Application

Chapter 4: Market Landscape
 4.1 Porter's Five Forces Analysis
  4.1.1 Bargaining Power of Supplier
  4.1.2 Threat of New Entrants
  4.1.3 Threat of Substitutes
  4.1.4 Competitive Rivalry
  4.1.5 Bargaining Power Among Buyers
 4.2 Industry Value Chain Analysis
 4.3 Market Dynamics
  4.3.1 Drivers
  4.3.2 Restraints
  4.3.3 Opportunities
  4.5.4 Challenges
 4.4 Pestle Analysis
 4.5 Technological Roadmap
 4.6 Regulatory Landscape
 4.7 SWOT Analysis
 4.8 Price Trend Analysis
 4.9 Patent Analysis
 4.10 Analysis of the Impact of Covid-19
  4.10.1 Impact on the Overall Market
  4.10.2 Impact on the Supply Chain
  4.10.3 Impact on the Key Manufacturers
  4.10.4 Impact on the Pricing

Chapter 5: Pharmacogenomics Technology (Theranostics and CDx) Market by Type
 5.1 Pharmacogenomics Technology (Theranostics and CDx) Market Overview Snapshot and Growth Engine
 5.2 Pharmacogenomics Technology (Theranostics and CDx) Market Overview
 5.3 Instruments
  5.3.1 Introduction and Market Overview
  5.3.2 Historic and Forecasted Market Size (2026-2035F)
  5.3.3 Key Market Trends, Growth Factors and Opportunities
  5.3.4 Instruments: Geographic Segmentation
 5.4 Reagents and Consumables
  5.4.1 Introduction and Market Overview
  5.4.2 Historic and Forecasted Market Size (2026-2035F)
  5.4.3 Key Market Trends, Growth Factors and Opportunities
  5.4.4 Reagents and Consumables: Geographic Segmentation
 5.5 Other
  5.5.1 Introduction and Market Overview
  5.5.2 Historic and Forecasted Market Size (2026-2035F)
  5.5.3 Key Market Trends, Growth Factors and Opportunities
  5.5.4 Other: Geographic Segmentation

Chapter 6: Pharmacogenomics Technology (Theranostics and CDx) Market by Application
 6.1 Pharmacogenomics Technology (Theranostics and CDx) Market Overview Snapshot and Growth Engine
 6.2 Pharmacogenomics Technology (Theranostics and CDx) Market Overview
 6.3 Tumour
  6.3.1 Introduction and Market Overview
  6.3.2 Historic and Forecasted Market Size (2026-2035F)
  6.3.3 Key Market Trends, Growth Factors and Opportunities
  6.3.4 Tumour: Geographic Segmentation
 6.4 Diabetes
  6.4.1 Introduction and Market Overview
  6.4.2 Historic and Forecasted Market Size (2026-2035F)
  6.4.3 Key Market Trends, Growth Factors and Opportunities
  6.4.4 Diabetes: Geographic Segmentation
 6.5 Mental Illness
  6.5.1 Introduction and Market Overview
  6.5.2 Historic and Forecasted Market Size (2026-2035F)
  6.5.3 Key Market Trends, Growth Factors and Opportunities
  6.5.4 Mental Illness: Geographic Segmentation
 6.6 Cardiovascular Disease
  6.6.1 Introduction and Market Overview
  6.6.2 Historic and Forecasted Market Size (2026-2035F)
  6.6.3 Key Market Trends, Growth Factors and Opportunities
  6.6.4 Cardiovascular Disease: Geographic Segmentation
 6.7 Other
  6.7.1 Introduction and Market Overview
  6.7.2 Historic and Forecasted Market Size (2026-2035F)
  6.7.3 Key Market Trends, Growth Factors and Opportunities
  6.7.4 Other: Geographic Segmentation

Chapter 7: Company Profiles and Competitive Analysis
 7.1 Competitive Landscape
  7.1.1 Competitive Positioning
  7.1.2 Pharmacogenomics Technology (Theranostics and CDx) Sales and Market Share By Players
  7.1.3 Industry BCG Matrix
  7.1.4 Heat Map Analysis
  7.1.5 Pharmacogenomics Technology (Theranostics and CDx) Industry Concentration Ratio (CR5 and HHI)
  7.1.6 Top 5 Pharmacogenomics Technology (Theranostics and CDx) Players Market Share
  7.1.7 Mergers and Acquisitions
  7.1.8 Business Strategies By Top Players
 7.2 GUARDANT HEALTH
  7.2.1 Company Overview
  7.2.2 Key Executives
  7.2.3 Company Snapshot
  7.2.4 Operating Business Segments
  7.2.5 Product Portfolio
  7.2.6 Business Performance
  7.2.7 Key Strategic Moves and Recent Developments
  7.2.8 SWOT Analysis
 7.3 BGI GROUP
 7.4 THERMO FISHER SCIENTIFIC
 7.5 QIAGEN
 7.6 ILLUMINA
 7.7 ABBOTT
 7.8 F. HOFFMANN-LA ROCHE
 7.9 AMOY DIAGNOSTICS
 7.10 AGILENT
 7.11 MGI TECH

Chapter 8: Global Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 8.1 Market Overview
 8.2 Historic and Forecasted Market Size By Type
  8.2.1 Instruments
  8.2.2 Reagents and Consumables
  8.2.3 Other
 8.3 Historic and Forecasted Market Size By Application
  8.3.1 Tumour
  8.3.2 Diabetes
  8.3.3 Mental Illness
  8.3.4 Cardiovascular Disease
  8.3.5 Other

Chapter 9: North America Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 9.1 Key Market Trends, Growth Factors and Opportunities
 9.2 Impact of Covid-19
 9.3 Key Players
 9.4 Key Market Trends, Growth Factors and Opportunities
 9.4 Historic and Forecasted Market Size By Type
  9.4.1 Instruments
  9.4.2 Reagents and Consumables
  9.4.3 Other
 9.5 Historic and Forecasted Market Size By Application
  9.5.1 Tumour
  9.5.2 Diabetes
  9.5.3 Mental Illness
  9.5.4 Cardiovascular Disease
  9.5.5 Other
 9.6 Historic and Forecast Market Size by Country
  9.6.1 US
  9.6.2 Canada
  9.6.3 Mexico

Chapter 10: Eastern Europe Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 10.1 Key Market Trends, Growth Factors and Opportunities
 10.2 Impact of Covid-19
 10.3 Key Players
 10.4 Key Market Trends, Growth Factors and Opportunities
 10.4 Historic and Forecasted Market Size By Type
  10.4.1 Instruments
  10.4.2 Reagents and Consumables
  10.4.3 Other
 10.5 Historic and Forecasted Market Size By Application
  10.5.1 Tumour
  10.5.2 Diabetes
  10.5.3 Mental Illness
  10.5.4 Cardiovascular Disease
  10.5.5 Other
 10.6 Historic and Forecast Market Size by Country
  10.6.1 Bulgaria
  10.6.2 The Czech Republic
  10.6.3 Hungary
  10.6.4 Poland
  10.6.5 Romania
  10.6.6 Rest of Eastern Europe

Chapter 11: Western Europe Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 11.1 Key Market Trends, Growth Factors and Opportunities
 11.2 Impact of Covid-19
 11.3 Key Players
 11.4 Key Market Trends, Growth Factors and Opportunities
 11.4 Historic and Forecasted Market Size By Type
  11.4.1 Instruments
  11.4.2 Reagents and Consumables
  11.4.3 Other
 11.5 Historic and Forecasted Market Size By Application
  11.5.1 Tumour
  11.5.2 Diabetes
  11.5.3 Mental Illness
  11.5.4 Cardiovascular Disease
  11.5.5 Other
 11.6 Historic and Forecast Market Size by Country
  11.6.1 Germany
  11.6.2 UK
  11.6.3 France
  11.6.4 Netherlands
  11.6.5 Italy
  11.6.6 Russia
  11.6.7 Spain
  11.6.8 Rest of Western Europe

Chapter 12: Asia Pacific Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 12.1 Key Market Trends, Growth Factors and Opportunities
 12.2 Impact of Covid-19
 12.3 Key Players
 12.4 Key Market Trends, Growth Factors and Opportunities
 12.4 Historic and Forecasted Market Size By Type
  12.4.1 Instruments
  12.4.2 Reagents and Consumables
  12.4.3 Other
 12.5 Historic and Forecasted Market Size By Application
  12.5.1 Tumour
  12.5.2 Diabetes
  12.5.3 Mental Illness
  12.5.4 Cardiovascular Disease
  12.5.5 Other
 12.6 Historic and Forecast Market Size by Country
  12.6.1 China
  12.6.2 India
  12.6.3 Japan
  12.6.4 South Korea
  12.6.5 Malaysia
  12.6.6 Thailand
  12.6.7 Vietnam
  12.6.8 The Philippines
  12.6.9 Australia
  12.6.10 New Zealand
  12.6.11 Rest of APAC

Chapter 13: Middle East & Africa Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 13.1 Key Market Trends, Growth Factors and Opportunities
 13.2 Impact of Covid-19
 13.3 Key Players
 13.4 Key Market Trends, Growth Factors and Opportunities
 13.4 Historic and Forecasted Market Size By Type
  13.4.1 Instruments
  13.4.2 Reagents and Consumables
  13.4.3 Other
 13.5 Historic and Forecasted Market Size By Application
  13.5.1 Tumour
  13.5.2 Diabetes
  13.5.3 Mental Illness
  13.5.4 Cardiovascular Disease
  13.5.5 Other
 13.6 Historic and Forecast Market Size by Country
  13.6.1 Turkey
  13.6.2 Bahrain
  13.6.3 Kuwait
  13.6.4 Saudi Arabia
  13.6.5 Qatar
  13.6.6 UAE
  13.6.7 Israel
  13.6.8 South Africa

Chapter 14: South America Pharmacogenomics Technology (Theranostics and CDx) Market Analysis, Insights and Forecast, 2026-2035
 14.1 Key Market Trends, Growth Factors and Opportunities
 14.2 Impact of Covid-19
 14.3 Key Players
 14.4 Key Market Trends, Growth Factors and Opportunities
 14.4 Historic and Forecasted Market Size By Type
  14.4.1 Instruments
  14.4.2 Reagents and Consumables
  14.4.3 Other
 14.5 Historic and Forecasted Market Size By Application
  14.5.1 Tumour
  14.5.2 Diabetes
  14.5.3 Mental Illness
  14.5.4 Cardiovascular Disease
  14.5.5 Other
 14.6 Historic and Forecast Market Size by Country
  14.6.1 Brazil
  14.6.2 Argentina
  14.6.3 Rest of SA

Chapter 15 Investment Analysis

Chapter 16 Analyst Viewpoint and Conclusion

Pharmacogenomics Technology (Theranostics and CDx) Scope:

Report Data	Pharmacogenomics Technology (Theranostics and CDx) Market
Pharmacogenomics Technology (Theranostics and CDx) Market Size in 2025	USD XX million
Pharmacogenomics Technology (Theranostics and CDx) CAGR 2025 - 2032	XX%
Pharmacogenomics Technology (Theranostics and CDx) Base Year	2024
Pharmacogenomics Technology (Theranostics and CDx) Forecast Data	2025 - 2032
Segments Covered	By Type, By Application, And by Regions
Regional Scope	North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
Key Companies Profiled	Guardant Health, BGI Group, Thermo Fisher Scientific, Qiagen, Illumina, Abbott, F. Hoffmann-La Roche, Amoy Diagnostics, Agilent, MGI Tech.
Key Segments	By Type Instruments Reagents and Consumables Other By Applications Tumour Diabetes Mental Illness Cardiovascular Disease Other